Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms

Journal of Proteomics

Volumn 75, Issue 4, 2012, Pages 1401-1410

  Fujii, Kazuyasu ^a   Suzuki, Norihiro ^a   Ikeda, Kazuko ^a   Hamada, Toshihisa ^a   Yamamoto, Takenobu ^a   Kondo, Tadashi ^b   Iwatsuki, Keiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

2D DIGE; Lymphoid neoplasms; Proteome database; Valproic acid

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE INHIBITOR; KNK 437; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA; PROTEOMICS; VALPROIC ACID;

EID: 84855879102     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.11.010     Document Type: Article

References (38)

1. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
2. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005, 14:1497-1511.
3. Marks P.A., Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551.
4. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
5. Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 2010, 19:1113-1127.
6. Erlich R.B., Rickwood D., Coman W.B., Saunders N.A., Guminski A. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009, 63:381-389.
7. Daud A.I., Dawson J., DeConti R.C., Bicaku E., Marchion D., Bastien S., et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009, 15:2479-2487.
8. Das C.M., Aguilera D., Vasquez H., Prasad P., Zhang M., Wolff J.E., et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007, 85:159-170.
9. Ciusani E., Balzarotti M., Calatozzolo C., de Grazia U., Boiardi A., Salmaggi A., et al. Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 2007, 16:453-463.
10. Marchion D.C., Bicaku E., Turner J.G., Daud A.I., Sullivan D.M., Munster P.N. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005, 11:8467-8475.
11. Zhou Q., Chaerkady R., Shaw P.G., Kensler T.W., Pandey A., Davidson N.E. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10:1029-1039.
12. Milli A., Cecconi D., Campostrini N., Timperio A.M., Zolla L., Righetti S.C., et al. A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells. Biochim Biophys Acta 2008, 1784:1702-1710.
13. Lee A.Y., Paweletz C.P., Pollock R.M., Settlage R.E., Cruz J.C., Secrist J.P., et al. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J Proteome Res 2008, 7:5177-5186.
14. Sanda T., Okamoto T., Uchida Y., Nakagawa H., Iida S., Kayukawa S., et al. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21:2344-2353.
15. Fuller H.R., Man N.T., Lam le T., Shamanin V.A., Androphy E.J., Morris G.E. Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells. J Proteome Res 2010, 9:4228-4233.
16. Cecconi D., Donadelli M., Dalla Pozza E., Rinalducci S., Zolla L., Scupoli M.T., et al. Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 2009, 9:1952-1966.
17. Buchi F., Pastorelli R., Ferrari G., Spinelli E., Gozzini A., Sassolini F., et al. Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. Leuk Res 2011, 35:921-931.
18. Fujii K., Kondo T., Yamada M., Iwatsuki K., Hirohashi S. Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2-D DIGE and MS. Proteomics 2006, 6:4856-4876.
19. Fujii K., Kondo T., Yokoo H., Yamada T., Iwatsuki K., Hirohashi S. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 2005, 5:1411-1422.
20. Covanis A., Gupta A.K., Jeavons P.M. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982, 23:693-720.
21. Khalil A.A., Kabapy N.F., Deraz S.F., Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?. Biochim Biophys Acta 2011, 1816:89-104.
22. Yokota S., Kitahara M., Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 2000, 60:2942-2948.
23. Bruzzese F., Leone A., Rocco M., Carbone C., Piro G., Caraglia M., et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011, 226:2378-2390.
24. Seo S.K., Jin H.O., Woo S.H., Kim Y.S., An S., Lee J.H., et al. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 2011, 6:1313-1319.
25. Yang C., Choy E., Hornicek F.J., Wood K.B., Schwab J.H., Liu X., et al. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 2011, 31:1115-1123.
26. Kondo T. Cancer proteome-expression database: genome medicine database of Japan proteomics. Expert Rev Proteomics 2010, 7:21-27.
27. Buhrens R.I., Amelung J.T., Reymond M.A., Beshay M. Protein expression in human non-small cell lung cancer: a systematic database. Pathobiology 2009, 76:277-285.
28. Fujii K., Kondo T., Yokoo H., Okano T., Yamada M., Yamada T., et al. Database of two-dimensional polyacrylamide gel electrophoresis of proteins labeled with CyDye DIGE Fluor saturation dye. Proteomics 2006, 6:1640-1653.
29. Mori Y., Kondo T., Yamada T., Tsuchida A., Aoki T., Hirohashi S. Two-dimensional electrophoresis database of fluorescence-labeled proteins of colon cancer cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 823:82-97.
30. Kosaihira S., Tsunehiro Y., Tsuta K., Tochigi N., Gemma A., Hirohashi S., et al. Proteome expression database of lund adenocarcinoma: a segment of the Genome Medicine Database of Japan Proteomics. J Proteome Bioinform 2009, 2:463-465.
31. Kikuta K., Tsunehiro Y., Yoshida A., Tochigi N., Hirohahsi S., Kawai A., et al. Proteome expression database of ewing sarcoma: a segment of the Genome Medicine Database of Japan Proteomics. J Proteomics Bioinform 2009, 2:500-504.
32. Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T. The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis. J Proteomics Bioinform 2009, 02:1-18.
33. Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6:3938-3948.
34. Mosser D.D., Morimoto R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907-2918.
35. Ma Y., Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer 2004, 4:966-977.
36. Nguyen A., Su L., Campbell B., Poulin N.M., Nielsen T.O. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009, 2009:794901.
37. Yerlikaya A., Okur E., Ekin S., Erin N. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep 2010, 3:333-339.
38. Johnson C.A., White D.A., Lavender J.S., O'Neill L.P., Turner B.M. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J Biol Chem 2002, 277:9590-9597.